恩扎鲁胺
前列腺癌
Wnt信号通路
癌症研究
雄激素受体
癌症
医学
连环素
下调和上调
肿瘤科
生物
信号转导
内科学
细胞生物学
生物化学
基因
作者
Zhuangzhuang Zhang,Lijun Cheng,Jie Li,Elia Farah,Nadia A. Lanman,Pete E. Pascuzzi,Sanjay Gupta,Xiaoqi Liu
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2018-04-26
卷期号:78 (12): 3147-3162
被引量:136
标识
DOI:10.1158/0008-5472.can-17-3006
摘要
Enzalutamide is a second-generation nonsteroidal antiandrogen clinically approved for the treatment of castration-resistant prostate cancer (CRPC), yet resistance to endocrine therapy has limited its success in this setting. Although the androgen receptor (AR) has been associated with therapy failure, the mechanisms underlying this failure have not been elucidated. Bioinformatics analysis predicted that activation of the Wnt/β-catenin pathway and its interaction with AR play a major role in acquisition of enzalutamide resistance. To validate the finding, we show upregulation of β-catenin and AR in enzalutamide-resistant cells, partially due to reduction of β-TrCP-mediated ubiquitination. Although activation of the Wnt/β-catenin pathway in enzalutamide-sensitive cells led to drug resistance, combination of β-catenin inhibitor ICG001 with enzalutamide inhibited expression of stem-like markers, cell proliferation, and tumor growth synergistically in various models. Analysis of clinical datasets revealed a molecule pattern shift in different stages of prostate cancer, where we detected a significant correlation between AR and β-catenin expression. These data identify activation of the Wnt/β-catenin pathway as a major mechanism contributing to enzalutamide resistance and demonstrate the potential to stratify patients with high risk of said resistance.Significance: Wnt/β-catenin inhibition resensitizes prostate cancer cells to enzalutamide. Cancer Res; 78(12); 3147-62. ©2018 AACR.
科研通智能强力驱动
Strongly Powered by AbleSci AI